On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.
about
The optimal threshold: Baseline serum hepatitis B virus DNA and alanine transaminase levels can predict the 2-Year on-treatment virological response to lamivudine.The cost-effectiveness of treating chronic hepatitis B patients in a median endemic and middle income country.Telbivudine for the treatment of chronic hepatitis B in HBeAg-positive patients in China: a health economic analysis.HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients.Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model.
P2860
On-treatment monitoring of HBV DNA levels: predicting response and resistance to oral antiviral therapy at week 24 versus week 48.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 30 July 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@en
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@nl
type
label
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@en
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@nl
prefLabel
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@en
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@nl
P2860
P1476
On-treatment monitoring of HBV ...... apy at week 24 versus week 48.
@en
P2093
Ting-Tsung Chang
P2860
P2888
P356
10.1007/S12072-009-9143-0
P478
P577
2009-07-30T00:00:00Z